Shreehas Tambe appointed CEO & MD of Biocon Limited from April 1, 2026, to lead integrated biosimilars and generics business globally.
Read Morebiosimilars
Biopharma SHAKTI Announced in Union Budget 2026-27 with ₹10,000 Crore Outlay
Union Budget 2026-27 introduces Biopharma SHAKTI with ₹10,000 crore outlay to boost biologics, biosimilars, healthcare skills and medical hubs.
Read More
Alkem launches Pertuza biosimilar in India for HER2-positive breast cancer treatment
Alkem launches Pertuza biosimilar in India, offering affordable HER2-positive breast cancer treatment and strengthening its oncology portfolio.
Read More
UDENYCA Acquired by Intas Pharmaceuticals and Accord BioPharma in Biosimilar Expansion
UDENYCA, a biosimilar to Amgen’s Neulasta, is indicated to reduce the risk of infection due to febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy.
Read More